Patient Education Webinar： Belzutifan
On May 14, 2025, the US Food and Drug Administration (FDA) approved belzutifan for adults and children over 12 years of age, who have pheochromocytoma (pheo) or paraganglioma (para) that has spread to nearby tissues, metastasized, not able to be removed surgically, or unable to be cured through other treatment options. The data from the clinical trial, that led to FDA approval, was presented at the ESMO Conference in mid-October by Dr. Camilo Jimenez. This education webinar, presented by Dr. Camilo Jimenez, is the first time that this data has been shared with the patient population. The information presented on this webinar is for educational purposes only and should not substitute the advice of your doctor(s) and medical team because they have in-depth knowledge of your medical history and current situation. Timings and questions are as follows: 58:10 -- Q1: Does tumor location factor into a treatment plan? And with that tumor location, if genetic versus non-genetic markers play into whether Belzutifan is a good treatment option? And VHL or non-VHL as well. 1:03:16 -- Q2: What are some considerations that there are in determining when in the treatment plan to take Belzutifan for metastatic pheo/para? Is there a good time to bring this up as well to maybe transition from something else that they might be taking? 1:07:34 -- Q3: Do you know any insight into whether Belzutifan is available internationally? 1:09:12 -- Q4: Is there something that was unique about the 15% or so (this is in reference to the trail) who did not respond to Belzutifan? Was there any type of genetics, tumor size, or anything that was unique to them? 1:10:18 -- Q5: Did you find any difference at all in responses between patients with a non-hormone secreting tumor versus those with hormone secreting? 1:11:27 -- Q6: If you're not metastatic, but have larger tumors that can't be surgically removed for various reasons, are you a possible candidate for Belzutifan? 1:12:30 -- Q7: Does it makes sense to get on Belzutifan instead of surgery even if surgery is possible? 1:14:47 -- Q8: Were there any concerns after the trial? Or did you see anything with any concerns for maybe long-term side effects from Belzutifan? Or did it seem like the results were increasing and getting better with time while during the trial? 1:18:12 -- Q9: Do normal hemoglobin levels matter in the decision to start Belzutifan? 1:20:12 -- Q10: Was there any results by age for the clinical trial that was published? 1:21:34 -- Q11: If I am stable metastic pheo or para, does it make sense to get on a treatment plan with Belzutifan to prevent future progression if I'm not currently on a treatment plan?
On May 14, 2025, the US Food and Drug Administration (FDA) approved belzutifan for adults and children over 12 years of age, who have pheochromocytoma (pheo) or paraganglioma (para) that has spread to nearby tissues, metastasized, not able to be removed surgically, or unable to be cured through other treatment options. The data from the clinical trial, that led to FDA approval, was presented at the ESMO Conference in mid-October by Dr. Camilo Jimenez. This education webinar, presented by Dr. Camilo Jimenez, is the first time that this data has been shared with the patient population. The information presented on this webinar is for educational purposes only and should not substitute the advice of your doctor(s) and medical team because they have in-depth knowledge of your medical history and current situation. Timings and questions are as follows: 58:10 -- Q1: Does tumor location factor into a treatment plan? And with that tumor location, if genetic versus non-genetic markers play into whether Belzutifan is a good treatment option? And VHL or non-VHL as well. 1:03:16 -- Q2: What are some considerations that there are in determining when in the treatment plan to take Belzutifan for metastatic pheo/para? Is there a good time to bring this up as well to maybe transition from something else that they might be taking? 1:07:34 -- Q3: Do you know any insight into whether Belzutifan is available internationally? 1:09:12 -- Q4: Is there something that was unique about the 15% or so (this is in reference to the trail) who did not respond to Belzutifan? Was there any type of genetics, tumor size, or anything that was unique to them? 1:10:18 -- Q5: Did you find any difference at all in responses between patients with a non-hormone secreting tumor versus those with hormone secreting? 1:11:27 -- Q6: If you're not metastatic, but have larger tumors that can't be surgically removed for various reasons, are you a possible candidate for Belzutifan? 1:12:30 -- Q7: Does it makes sense to get on Belzutifan instead of surgery even if surgery is possible? 1:14:47 -- Q8: Were there any concerns after the trial? Or did you see anything with any concerns for maybe long-term side effects from Belzutifan? Or did it seem like the results were increasing and getting better with time while during the trial? 1:18:12 -- Q9: Do normal hemoglobin levels matter in the decision to start Belzutifan? 1:20:12 -- Q10: Was there any results by age for the clinical trial that was published? 1:21:34 -- Q11: If I am stable metastic pheo or para, does it make sense to get on a treatment plan with Belzutifan to prevent future progression if I'm not currently on a treatment plan?